Investor Meetings

The conference room goes quiet. Three partners lean forward, notebooks open, and you've just finished your pitch. Now comes the moment that actually determines your funding:

"What's your regulatory timeline?"

"How will payers cover this?"

"Why won't Company X just copy you?"

These aren't hostile questions. They're the standard scrutiny every MedTech founder will face. How you answer in the next thirty minutes matters more than the previous thirty. Founders who anticipate these challenges, provide credible answers grounded in data, and demonstrate strategic depth walk out with term sheets. Those who stumble, deflect, or offer superficial responses will see their opportunity fade to nothing.

Clarifying the regulatory pathway

‘What's your FDA or CE marking path and when do you expect approval?’ This question will come up in virtually every investor meeting. Founders who provide vague timelines or demonstrate regulatory naivety trigger immediate concerns about team capability and capital efficiency. Present your regulatory strategy with precision, specify your device classification under the FDA, MDR, and MHRA frameworks, and explain which approval pathway you'll pursue, including 510(k) predicate devices, de novo classification, PMA requirements, or CE marking conformity assessment routes. Detail the clinical evidence requirements for your chosen pathway.

Provide staged timeline projections showing key regulatory milestones. Include design freeze dates, verification and validation completion, technical file compilation, submission dates, and expected approval timelines. Add buffers for realistic delays, including additional information requests or review cycles.

Investors have funded too many medical device companies that underestimated regulatory complexity and burned through capital pursuing unclear pathways. Show you've consulted with regulatory specialists, understand classification nuances, and built realistic timelines with contingency plans. We're funding teams that demonstrate a sophisticated understanding of the approval process they're entering.

_{Hermann Hauser, co-founder Amadeus Capital Partners}

Demonstrating reimbursement viability

Regulatory approval without reimbursement coverage creates worthless assets. Research applicable reimbursement codes thoroughly. Explain how your device fits within NHS tariff structures, and across European markets, detail which DRG systems will apply. If existing codes cover your device, explain this with supporting evidence. If you require new codes or enhanced rates, add this to your application strategy, including timelines and required evidence.
Present input from your key opinion leader to support explicitly. Present a health economic analysis demonstrating cost-effectiveness, showing that your device reduces total treatment costs through fewer complications or shorter procedures, or that clinical benefits justify any cost premium.

Addressing competitive threats

Address competitive dynamics honestly. Acknowledge that large companies possess formidable advantages, including established customer relationships, regulatory expertise, and distribution networks. Explain your defensibility through multiple mechanisms. Strong intellectual property, including issued patents covering core innovations, will provide durable protection. Detail your patent portfolio and explain what competitors cannot easily design around.
Speed to market often matters more than patent strength. If you can achieve regulatory approval and build market presence before large competitors prioritise your segment, you will establish relationships that create switching costs. Strategic partnerships can provide protection simultaneously, and if you've secured development partnerships or investment from strategics, these relationships will validate your technology and potentially deter competitive threats.

Projecting path to profitability

Showing when you’ll become profitable will create investor focus on capital efficiency and return timelines. Founders who cannot articulate unit economics and breakeven projections signal inadequate commercial thinking. Present your unit economics with transparency. Show device manufacturing costs, gross margins, customer acquisition costs, and contribution margins per unit. Investors expect 60% to 75% gross margins for most medical devices. Project revenue growth based on realistic adoption curves. Model sales force productivity, average territory sizes, and customer acquisition timelines. Calculate breakeven timing, showing when cumulative revenue will exceed cumulative costs.

Show that you've built conservative models with realistic assumptions about sales cycles, pricing pressure, and adoption rates. We're more impressed by founders who acknowledge uncertainty and model multiple scenarios than those who present single optimistic projections with false precision.

_{Aisling Burnand. Chief Executive BioIndustry Association}

Include sensitivity analysis showing how profitability timing changes when key assumptions prove incorrect. Model the scenarios where pricing comes under pressure, adoption proceeds more slowly, or manufacturing costs exceed projections.

Presenting clinical evidence

Investors need proof that your technology works as claimed and will deliver meaningful improvements over its alternatives. Present existing evidence systematically to include bench testing results, animal study outcomes, or human pilot data. Show the sample sizes tested, outcome measures assessed, and results achieved. Compare performance against relevant benchmarks, then detail your clinical trial roadmap if pivotal human studies remain ahead. Explain study design, patient population, primary endpoints, sample size calculations, and site selection. Provide realistic timelines from protocol development through enrolment completion.

Address data gaps honestly. If you lack clinical evidence in specific patient populations or long-term follow-up, acknowledge these limitations while explaining how you'll address them in future.

Preempting concerns through risk mitigation

The most sophisticated founders anticipate investor concerns and address them proactively. Include a risks and mitigations slide outlining key threats and your strategies for managing them. Regulatory risk represents the most common concern. For example, if an FDA review extends beyond projections, choose whether you’ll pursue CE marking first. If evidence requirements exceed assumptions, check your backup study designs. Commercial risk with adoption and pricing requires mitigation strategies. If reimbursement proves slower than expected, make sure to target international territories. Should pricing pressure emerge, your unit economics will support lower price points.

Competitive risk from incumbents demands credible defensive strategies. Beyond patents, see what customer relationships, clinical data, or strategic partnerships will provide protection. Financial risk demands clear planning. If your development costs exceed projections, decide which activities you can defer. When fundraising markets deteriorate, you’ll need to be clear on the alternatives that exist, including grants and strategic partnerships.

Pre-investor meetings workshop

Successful investor meetings begin relationships where investors gain confidence in your team, understand your technology, and believe you can execute despite challenges. With the VP Med Ventures investor meeting workshop, we can help ensure you’re ready to anticipate hard questions, provide more credible answers, and demonstrate your depth of thinking. By addressing your weaknesses proactively, these conversations will convert interest into capital and transform investors into partners. People who will support your journey from prototype to patient impact.

Waypoint checklist

Keep in mind the following questions that might just come up:

• What’s your FDA/CE path and approval ETA?
• How will payers cover this?
• Why won’t Medtronic crush you?
• When do you turn a profit?
• Where’s the data?
• Preempt these questions by adding a risks & mitigations slide.

‍